San Francisco, August 25, 2018 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that its Chief Scientific Officer, Darrell Nix, Ph.D., presented today the findings of a Phase 1 study of its lead drug candidate dutogliptin for the treatment of patients in early recovery post-myocardial infarction.
San Francisco, June 28th,2018 – Recardio Inc. today announced that it has expanded its Management Board, reflecting the companies expansion of clinical development in 2018.
This newly formed Management Board represents a selection of professionals with longlasting business experience, who already contributed to the past development.
The following new positions were appointed to the Management Board being effective by June 2018:
Dr. Stephan Henauer, MD as Chief Medical Officer
Dr. Frank Hanakam, PhD, MBA as Chief Manufacturing Officer
Frank Ahmann, MBA as Chief Operating Officer
Antonia Klopfer as Chief Financial Officer
Dr. Roman Schenk, RECARDIO Executive Chairman commented: “We are extremely proud that we have successfully expanded our Management Board by these unique board members, who already contributed or will contribute with their excellent and long-lasting experience to our corporate development and sucess.”
Recardio Inc. is a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases. The company’s lead drug candidate, dutogliptin, is a DPP-IV inhibitor that has demonstrated significant effects in activating SDF-1, a protein that is critical for cardiac regeneration. The company is pursuing a Phase 2 clinical program, seeking to fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases including acute myocardial infarction and chronic heart failure, with the potential of improving heart function, quality of life and survival. For more information, visit: http://www.recardio.eu/
San Francisco, May 28, 2018 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that it is starting recruiting patients for its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction. Recruitment for this randomized, double-blind, placebo-controlled trial will begin in one of the 29 participating trial centers in the European Union and be expanded rapidly to also include 5 centers in the United States.
San Francisco, January 31st, 2018 – Recardio Inc. today announced that it has received the FDA approval for its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction.
San Francisco, Oct. 17, 2017 – Recardio presented today its clinical regenerative therapy program for cardiovascular diseases at the international BIO Investor Forum 2017 in San Francisco.